1200 results for "Ayahuasca"
Screening the receptorome for plant-based psychoactive compounds.
Life sciences – December 22, 2005
Summary
Many powerful plant-based compounds influence our brains by targeting specific cellular receptors. A new high-throughput system was developed to systematically uncover how these natural compounds interact with the body's vast network of receptors. This innovative screening successfully identified the precise molecular targets for psychoactive compounds found in plants like Salvia divinorum and Banisteriopsis caapi, offering a powerful tool for discovering beneficial plant-derived substances.
Abstract
Throughout time, humans have used psychoactive plants and plant-derived products for spiritual, therapeutic and recreational purposes. Furthermore,...
Altered consciousness states and endogenous psychoses: a common molecular pathway?
Schizophrenia research – December 19, 1997
Summary
No Summary
Abstract
Interest in the role of indolamines in the pathogenesis of psychoses has been renewed in recent years by the development of atypical antipsychotic ...
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study
Frontiers in Psychiatry – June 16, 2021
Summary
Regular psychedelic users reported significantly less psychological distress during the initial COVID-19 lockdowns. A survey of 2,974 individuals (70% female) showed that those regularly using psychedelics, including psilocybin, experienced reduced peritraumatic stress and more social support. This finding, crucial for mental health and clinical psychology, suggests either protective effects or distinct personality traits within this population. Such insights are vital for psychology, psychiatry, and medicine, advancing our understanding in psychedelics and drug studies.
Abstract
Background: One of the main public health strategies adopted at the beginning of the COVID-19 pandemic consisted of implementing strict lockdowns t...
Ancient psychoactive plants in a global village: The ritual use of cannabis in a self-managed community in Catalonia.
The International journal on drug policy – December 01, 2021
Summary
No Summary
Abstract
Cannabis is a plant with a rich history of medical, recreational, industrial and spiritual uses. This paper aims to explore drug use rituals as met...
Teacher plants - Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives.
Journal of ethnopharmacology – March 25, 2022
Summary
No Summary
Abstract
Indigenous groups of the Amazon have developed intricate methods for the application of psychoactives, among which particularly the dieta or diet m...
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Biomedicine & Pharmacotherapy – December 31, 2023
Summary
Understanding how the body processes psychedelic compounds is vital for unlocking their therapeutic potential. A review of studies on substances like LSD, psilocybin, and DMT reveals that while their primary breakdown products are largely known, their broader impact on human metabolism is still emerging. Integrating advanced metabolomics with drug tracking promises to illuminate the precise molecular interactions behind their positive therapeutic effects, paving the way for novel treatment development.
Abstract
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attentio...
Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.
Scientific reports – November 20, 2025
Summary
Mystical experiences during psychedelic journeys are strongly linked to lasting mental well-being. A clinical study explored an encapsulated DMT-harmala combination. Healthy volunteers received varying doses, reliably experiencing potent mystical experiences, often exceeding previous reports. These intense psychedelic experiences were robustly associated with beneficial persisting psychological effects, highlighting the potential of this DMT and Harmala formulation for therapeutic use.
Abstract
Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical ...
Synthesis and characterization of high‐purity N,N‐dimethyltryptamine hemifumarate for human clinical trials
Drug Testing and Analysis – July 01, 2020
Summary
A highly pure form of the psychedelic DMT is now ready for clinical trials, crucial for advancing drug studies. Through novel chemical synthesis, using aluminum hydride from lithium aluminum hydride, a DMT hemifumarate salt was produced. Extensive chemistry analysis—mass spectrometry, differential scanning calorimetry, thermogravimetric analysis, nuclear magnetic resonance, and chromatography—confirmed minimal 99.9% purity. This rigorous standard, essential across all drug studies from cannabis to other alkaloids, ensures safety. No significant impurities or residual lithium were detected, meeting regulatory requirements.
Abstract
Abstract Since 2006, there has been a resurgent interest in the pharmacology and therapeutics of psychedelic drugs. Psilocybin, the 4‐phosphoryl es...
Psilocybin, psychological distress, and suicidality
Journal of Psychopharmacology – September 01, 2015
Summary
Lifetime psilocybin use significantly correlates with reduced psychological distress and suicidality. Among 191,832 U.S. adults, those reporting only psilocybin (a potent hallucinogen) use (2.47% of the sample) exhibited the greatest reductions in distress and suicidal thoughts, planning, and attempts. This finding, crucial for Psychology and Clinical Psychology, suggests psilocybin's potential in Psychiatry and Medicine. It offers psychotherapists a new avenue within Psychedelics and Drug Studies for managing psychological distress, hinting at its unique chemical synthesis and influence on behavior.
Abstract
Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid di...
Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
OpenAlex – June 10, 2021
Summary
Psychedelics like psilocybin show promising efficacy for psychiatric conditions, driving interest in their neurocognitive effects. Functional magnetic resonance imaging (fMRI) is a key neuroimaging tool, with 42 articles analyzing resting-state fMRI data from 17 unique datasets on drug effects. However, this field of Psychedelics and Drug Studies faces significant methodological heterogeneity. Nearly all studies vary in data processing, and over half the literature stems from just two datasets. To advance understanding of functional brain connectivity in neuroscience and psychology, greater consistency and replicability are crucial.
Abstract
Clinical research into serotonergic psychedelic drugs including psilocybin, LSD and N,N-DMT (e.g., in ‘ayahuasca’) is expanding rapidly and clinica...
Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year
Hypertension – March 08, 2021
Summary
Adults reporting lifetime classic psychedelic use showed a 14% lower likelihood of hypertension, a significant association with implications for medicine. Analyzing US survey data from 2005-2014, these drug studies reveal a particularly strong connection with tryptamines, which are structurally similar to tryptophan and influence neurotransmitter receptor activity. Lifetime tryptamine use was linked to a 20% lower likelihood of high blood pressure. This intriguing finding suggests a potential role for psychedelics in cardiovascular health, impacting our understanding of brain disorders and their treatment.
Abstract
Using data from the National Survey on Drug Use and Health (2005–2014), weighted to be representative of the US adult population, the present study...
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Acta Psychiatrica Scandinavica – October 30, 2020
Summary
Serotonergic hallucinogens like psilocybin show remarkable promise, offering 188 patients long-lasting relief from anxiety and major depressive disorder after just 1-3 sessions. This burgeoning field of clinical psychology and medicine, grounded in careful psychedelics and drug studies, reviewed 16 papers. It confirms these compounds, influencing neurotransmitter receptors, are safe, reporting no severe adverse effects. Psychiatry is exploring these naturally derived or chemically synthesized agents as powerful new tools for psychotherapists, addressing significant unmet needs in mental health.
Abstract
Abstract Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies assessing the therapeutic effects of serotonergi...
“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin
Journal of Psychedelic Studies – October 29, 2024
Summary
For mental health, whole Psilocybe mushrooms and their extracts offer a more natural and superior experience than synthetic psilocybin. Participants in a Psilocybin-Assisted Therapy program for end-of-life distress reported that while synthetic psilocybin, whole *Psilocybe cubensis*, and mycological extract all provided emotional insight and mystical experiences, synthetic psilocybin felt less natural and had an inferior overall quality. This suggests future Psychedelics and Drug Studies in psychology and psychiatry should prioritize natural mushroom compounds in medicine, moving beyond synthetic drug forms.
Abstract
Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such...
Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample
OpenAlex – February 28, 2025
Summary
Individuals with high lifetime involvement in psychedelic-assisted therapy (PAT) report elevated depression and anxiety, a compelling finding from a cross-sectional study. Analyzing a nonprobability sample of 244 PAT patients, a latent class model identified three groups: High-PAT (55.7%), Medium-PAT (29.1%), and a unique Psilocybin-Ketamine class (15.2%). This psychology-focused research suggests a link between extensive PAT engagement and mental health challenges, informing clinical psychology, medicine, and psychiatry regarding these psychedelics.
Abstract
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional ...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
ACS Chemical Neuroscience – July 23, 2018
Summary
N, N-dimethyltryptamine (DMT), a potent hallucinogen, is remarkably ubiquitous, produced by diverse plant and animal species, and even endogenously in mammals. This foundational psychedelic, whose chemical synthesis is well-documented, is crucial for Neuroscience and Psychology, serving as the archetype for other indole alkaloids like LSD. Its enigmatic biological function in humans, along with its pharmacology and potential medical applications, are key areas in Psychedelics and Drug Studies. Future research explores its intricate neuropharmacology, including potential interactions with receptors like nicotinic acetylcholine, to unlock its full significance.
Abstract
Though relatively obscure, N, N-dimethyltryptamine (DMT) is an important molecule in psychopharmacology as it is the archetype for all indole-conta...
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Pharmacopsychiatry – January 20, 2021
Summary
Compelling clinical trials show psilocybin and lysergic acid diethylamide (LSD), powerful hallucinogens, are re-emerging in psychiatry. Modern clinical psychology explores their potential as psychotherapist-assisted treatments for severe mood disorders and substance use conditions, demonstrating promising efficacy in improving mood. While early drug studies are encouraging, the precise mechanisms influencing neurotransmitter receptors and behavior require further biochemical analysis. Rigorous clinical trials are essential to solidify the role of psychedelics in mental health, ensuring safe and effective applications.
Abstract
Abstract Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have been used and extensively studied in Western medic...
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
Therapeutic Advances in Psychopharmacology – January 01, 2019
Summary
Serotonergic hallucinogens like psilocybin significantly reduce the recognition of negative facial expressions, a key aspect of cognitive psychology. A review of 8 studies, from 62 identified in Psychedelics and Drug Studies, revealed that drugs such as LSD modulate amygdala activity. This neuroscience finding suggests a neurotransmitter receptor influence on behavior, potentially aiding psychotherapists. These compounds, derived from chemical synthesis and alkaloids, were well-tolerated and correlated with antidepressive effects, offering promising insights for psychotherapeutic applications.
Abstract
Background: Recognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated wit...
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Australian & New Zealand Journal of Psychiatry – March 21, 2021
Summary
Psilocybin and other psychedelics show immense promise for mental health, potentially revolutionizing psychiatry. Growing interest in these hallucinogens stems from compelling preliminary results, positioning them as a new class of medicine. Psychotherapist-guided treatments, focusing on neurotransmitter receptor influence on behavior, are key. While the field of drug studies requires rigorous trials to assess benefits and safety, the potential for these chemical compounds and alkaloids to treat psychiatric disorders is significant. Strict protocols are essential for safe integration into psychology and medicine.
Abstract
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attract...
How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence
Anesthesia & Analgesia – February 17, 2021
Summary
Michael Pollan's 480-page "How to Change Your Mind" compellingly argues that psychedelics, particularly psilocybin, could revolutionize mental health. Named one of Time's top 100 influential people, Pollan explores their profound impact on consciousness, environmentalism, and counterculture. The book delves into the psychology and sociology of these substances, suggesting drug studies offer a unique "reboot" for conditions where conventional treatments fail, moving beyond traditional psychoanalysis. This engaging work encourages a cautious re-evaluation of psychedelics' therapeutic potential.
Abstract
It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind e...
The Consumption of Psychoactive Plants in Ancient Global and Anatolian Cultures During Religious Rituals: The Roots of the Eruption of Mythological Figures and Common Symbols in Religions and Myths
NeuroQuantology – May 31, 2014
Summary
Visions from ancient psychedelic plant consumption profoundly shaped global mythology. For centuries, a vast array of cultures, from Aztec to Hellenic, engaged in ritualistic consumption of psychoactive plants like psilocybin and ibogaine. These powerful experiences, central to ancient history and drug studies, generated vivid illusions. The aesthetics of these "plant trips" directly influenced the creation of countless mythological characters, gods, and demons, impacting literature and religious narratives across numerous societies. This fundamental link between psychedelics and the bedrock of human storytelling remains widely underestimated.
Abstract
Psychoactive plants which contain hallucinogenic molecules that induce a form of altered states of consciousness (H-ASC) have been widely used duri...
Novel antidepressant drugs: Beyond monoamine targets
CNS Spectrums – September 30, 2021
Summary
Millions struggle with Major depressive disorder, yet current antidepressant medicine targeting monoamine neurotransmitters like dopamine often fails on efficacy or tolerability. New pharmacology in psychiatry and psychology is exploring pathways beyond these. For instance, nine glutamatergic and GABAergic drugs are in development. Furthermore, Psychedelics and Drug Studies show promise, with compounds like psilocybin, relevant to tryptophan and brain disorders, offering novel treatment of Major Depression. This expanded strategy aims for superior outcomes.
Abstract
Abstract Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are...
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
ACS Pharmacology & Translational Science – March 11, 2021
Summary
Recent clinical psychology trials show no increased suicidal ideation with psychedelic therapy, offering hope for mental health. A review of 64 articles, 41 on non-clinical hallucinogen use (like psilocybin and lysergic acid diethylamide) and 23 on therapy, explored this association. While early psychiatry cases noted suicides, modern Psychedelics and Drug Studies indicate acute and sustained decreases in suicidal ideation. Understanding these substances, from chemical synthesis and alkaloids to their forensic toxicology, is crucial for psychotherapists.
Abstract
Use of classic psychedelics (e.g., psilocybin, ayahuasca, and lysergic acid diethylamide) is increasing, and psychedelic therapy is receiving growi...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Current Neuropharmacology – January 05, 2024
Summary
With 12 million U.S. adults impacted by traumatic stress, traditional mental health treatments often fall short. Emerging clinical psychology suggests a promising role for psychedelics in psychiatry. Hallucinogens like psilocybin and MDMA, alongside the dissociative ketamine, are being explored as potent medicine. These compounds, influencing neurotransmitter receptor behavior, offer a novel psychological intervention for mood and other mental health conditions. Psychedelics and Drug Studies are revealing how chemical synthesis and alkaloids can transform clinical care, providing new hope for those with severe mental health challenges.
Abstract
Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estima...
Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
Contemporary Drug Problems – September 01, 2019
Summary
Feeling euphoric (58.0%), enhancing activities (52.3%), and broadening consciousness (48.1%) are key motives for using psychoactive substances. A survey of 1,967 adults explored motivations for traditional psychoactive drugs like Cannabis, MDMA, Ecstasy, Psilocybin, and Lysergic acid diethylamide (LSD), alongside designer drugs and synthetic cannabinoids. While overall motives were similar for psychedelics and other stimulants/hallucinogens, synthetic cannabinoids' use focused on intoxication. Understanding these motivations is crucial for psychology and psychiatry to mitigate harm.
Abstract
Novel psychoactive substances (NPS) are compounds designed to mimic the effects of existing recreational drugs (classical psychoactive substances [...
Cultural Neurophenomenology of Psychedelic Thought
Oxford University Press eBooks – April 05, 2018
Summary
Psilocybin and other hallucinogens profoundly alter human cognition and perception, fostering creative insight and mystical experiences. Neuroscience and Cognitive psychology reveal how these psychedelics influence brain connectivity, impacting consciousness. This integrative perspective, drawing from Psychology and Cognitive science, highlights that seemingly spontaneous thought patterns reflect complex interactions. Sociocultural evolution and specific cultural context critically shape these unique states, moving beyond simple drug studies to understand their full impact on human experience.
Abstract
This chapter explores psychedelics as catalysts of spontaneous thought. Classic serotonergic psychedelics such as psilocybin, LSD, and ayahuasca ca...
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications
Journal of Music Therapy – January 01, 2020
Summary
Music is integral to psychedelic therapy, acting as both anchor and guide during emotional and embodied experiences. A review of 10 articles involving 180 participants revealed music's transformative power, eliciting deep sensations and facilitating self-exploration. In Psychedelics and Drug Studies, compounds like psilocybin and lysergic acid diethylamide (from chemical synthesis and alkaloids) are paired with music. This highlights a crucial role for music therapy and psychotherapists in Psychology, optimizing protocols for these emerging treatments, linking to Complementary and Alternative Medicine Studies. Participant openness to music improved outcomes.
Abstract
Abstract Bonny Method of Guided Imagery and Music emerged following discontinuation of psychedelic therapy research in the early 1970s, but psyched...
Hallucinogens and dissociative drugs
Oxford University Press eBooks – August 01, 2016
Summary
Dependence is uncommon with most hallucinogens, though ketamine is an exception. This Addiction Medicine chapter details a wide array of psychedelics like psilocybin and LSD, alongside dissociative drugs such as PCP. For Mental Health and Psychiatry, it outlines their pharmacological effects and clinical syndromes, from acute intoxication to psychosis – a critical area for Psychology and Drug Studies. Flashbacks are a characteristic feature. Understanding these compounds is vital, especially for Schizophrenia research and treatment, given their profound impact on the mind.
Abstract
Abstract Chapter 15 of Addiction Medicine covers hallucinogens and dissociative drugs. Hallucinogens are a large and diverse group of substances, s...
Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative
Anthropology of Consciousness – August 22, 2022
Summary
Psychedelic medicines, long central to Indigenous and counterculture wisdoms, are now driving multimillion-dollar IPOs in Medicine and Psychiatry. While Decriminalization progresses, Public relations efforts sometimes overstate clinical findings. Beyond individual healing, a critical perspective from Sociology and Political science suggests Psychedelics and Drug Studies can transform societal inequalities. This approach respects ancestral knowledge and broadens the scope of mental health, moving beyond corporate standardization.
Abstract
Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post‐traumatic stress disorder, can...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
Sexual & Relationship Therapy – October 20, 2021
Summary
Psychedelic integration therapy offers remarkable healing for human sexuality and trauma. Guided by a psychotherapist, individuals using natural compounds like psilocybin report profound embodied pleasure, liberated from shame. This psychological approach fosters a healthy identity and increased sexual satisfaction, addressing deep-seated issues that can underpin addiction. Clients describe direct, existential meaning through divine connection, facilitating sustained well-being. This innovative area within psychedelics and drug studies holds significant promise.
Abstract
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, ...
Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy
Psychiatric News – August 15, 2023
Summary
Australia has become the first nation to legalize psilocybin and MDMA for medical use in clinical psychology, targeting PTSD and treatment-resistant depression. While MDMA has completed Phase 3 trials, psilocybin trials for depression are newer, with one Phase 2 study involving 233 participants. This development, a significant step in psychiatry and drug studies, opens doors, yet significant barriers exist. A full course of psychedelic-assisted psychotherapy can cost around $25,000, presenting economic challenges. Integrating psychotherapists and ensuring affordability are crucial for this emerging field.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessAustralia Legalizes Psychedelics for Use in Depression, PTSD ...
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
Frontiers in Pharmacology – September 29, 2021
Summary
Tryptamine hallucinogens like Psilocybin strongly modulate key brain regions, holding therapeutic promise in Psychology. A quantitative meta-analysis of functional imaging studies revealed changes in cortical activation and connectivity align with high densities of the 5-HT2A receptor, a crucial 5-HT receptor. Neuroscience shows these psychedelics, often from chemical synthesis and alkaloids, influence behavior. Affected areas include the anterior cingulate cortex, posterior cingulate, ventromedial prefrontal cortex, dorsolateral prefrontal cortex, and temporal cortex. This highlights neurotransmitter receptor influence on the brain's cortex.
Abstract
There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by t...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
American Journal of Therapeutics – March 01, 2024
Summary
MDMA, a synthetic drug, demonstrates superiority over existing treatments for post-traumatic stress disorder in two completed Phase III clinical trials. This highlights the growing potential of psychedelics as medicine in psychiatry. While psilocybin, a naturally occurring hallucinogen, shows a 25-29% depression remission rate in larger trials (100+ participants)—comparable to standard antidepressants at 30%—other compounds like lysergic acid diethylamide and the dissociative Esketamine are also being explored. Understanding their pharmacology and potential adverse effects is crucial as these drug studies advance.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
Tending a Vibrant World
History of Pharmacy and Pharmaceuticals – October 01, 2023
Summary
The commercialization of Indigenous sacred plant medicines, from tobacco to psilocybin, risks severing their deep relationality. Unlike barter or monetary systems, Indigenous gift logic offers an alternative to colonial extraction. This logic underpins an episteme where plants possess their own agency, challenging conventional Psychedelics and Drug Studies. Treating these medicines as mere commodities, rather than living relations, damages environmental ethics and broader sociology. Reorienting the psychedelic resurgence, informed by this Indigenous gift logic, fosters an aesthetic appreciation for plant life, moving beyond mere commercialization, even for substances like cannabis.
Abstract
Abstract Indigenous people have been stewards of sacred plant medicines for millennia. Many of these sacred medicines—such as tobacco, cedar, sage,...
Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2
The Journal of Clinical Psychiatry – February 23, 2021
Summary
High-dose psilocybin, a potent hallucinogen, significantly reduced Major Depressive Disorder and Anxiety in a randomized controlled trial of 51 cancer patients, sustained in 80% at six months. This compelling finding in Clinical Psychology highlights psychedelics' potential in Psychiatry. Psilocybin, Lysergic acid diethylamide, and MDMA are gaining traction in Medicine, exploring their neurotransmitter receptor influence on behavior to improve mood. Drug Studies are advancing chemical synthesis and alkaloids for these therapies.
Abstract
P sychedelics have recently gained attention as compounds with therapeutic potential in the treatment of psychiatric disorders.The US Food and Drug...
Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
OpenAlex – July 13, 2022
Summary
Mind-altering drugs profoundly reorganize brain function by engaging intricate neurotransmitter systems. Neuroscience and Neuropharmacology Research demonstrates that psychoactive substances, including 10 diverse drugs like psychedelics (LSD, psilocybin) and anesthetics, exert their effects based on the brain's molecular makeup. By mapping 19 neurotransmitter receptors and transporters, a clear link emerged between specific neurotransmitter receptor influence on behavior and drug-induced changes. This work in Psychology and Medicine highlights how pharmacology precisely targets brain regions, revealing patterns that even mirror those seen in brain disorders.
Abstract
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage ...
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
Canadian Journal of Health Technologies – June 24, 2021
Summary
Psychedelics show significant potential in medicine, improving mental health symptoms with no serious adverse events. One randomized controlled trial found psilocybin-assisted psychotherapy efficacious for mood disorders like depression. Across two systematic reviews and three randomized controlled trials, various hallucinogens, including MDMA, combined with psychotherapist support, demonstrated clinical effectiveness for conditions like anxiety. This growing area in clinical psychology and psychiatry, part of broader drug studies, explores how these compounds, often from chemical synthesis, influence behavior. Sample sizes were typically under 20, warranting further investigation.
Abstract

 Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations o...
Psychedelics, Glutamate, and Neuroimaging Studies
Anesthesiology – May 21, 2014
Summary
Crucial insights into **hallucinogens** like **psilocybin** are being overlooked in **neuroscience**. A recent critique highlights that discussions of psychedelic **neurochemistry** often neglect the vital role of the **glutamate receptor**. Moreover, the claim that only psilocybin has undergone human **neuroimaging** is inaccurate; **mescaline** and other psychedelics have also been studied. These omissions in **pharmacology** and **medicine** impede a comprehensive understanding of **Psychedelics and Drug Studies**, impacting our grasp of **psychology** and **Neurotransmitter Receptor Influence on Behavior**.
Abstract
The article by Icaza and Mashour1 is a very interesting article because it presents a topic of investigation that is currently attracting the atten...
Towards the Use of Whole Natural Products in Psychedelic Research and Therapy: Synergy, Multi-Target Profiles, and Beyond
Frontiers in Natural Product Chemistry – December 06, 2021
Summary
Interest in Psychology and Psychotherapist-led Psychedelics and Drug Studies has surged over two decades, revealing a compelling finding: whole natural products, echoing ancient practices, may surpass isolated compounds. Instead of single molecules from chemical synthesis and alkaloids, a "polypharmacology" approach posits that complex mixtures, understood through biochemical analysis and sensing techniques, are more effective. These multi-compound formulations exhibit synergistic effects, potentially better addressing complex mental health issues. This paradigm advocates for integrating whole natural products into psychedelic-assisted therapy.
Abstract
Interest in psychoactive ethnobotanicals such as ayahuasca or Psilocybe mushrooms for clinical uses has increased over the last two decades. While ...
Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports
Journal of Psychedelic Studies – July 17, 2024
Summary
Users of 5-MeO-DMT, a potent hallucinogen, strongly perceived a need for care. Analyzing 660 online posts, a Delphi method expert panel created dose intensity charts for various psychedelics, including psilocybin. While oral administration was common for lower doses, greater drug purity from chemical synthesis and alkaloids, and higher doses, correlated with a perceived need for support. This work, vital for Psychology and Psychedelics and Drug Studies, informs medicine, guiding future biochemical analysis of substances like mescaline.
Abstract
Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing bot...
Psychedelics for Psychiatric Disorders: Promise, Not Panacea
Psychiatric Annals – September 01, 2022
Summary
Psilocybin, a potent hallucinogen, significantly reduces end-of-life anxiety in cancer patients and shows promise for depression and addiction. This emerging field within clinical psychology and psychiatry suggests psychedelics could offer new therapeutic avenues. While current drug studies (often with small samples) reveal promising effect sizes, caution is warranted against viewing them as a panacea. Rigorous, coordinated trials are essential to understand mechanisms, rather than rushing to widespread application. Future research must compare these alkaloids to existing treatments like Sertraline, addressing forensic toxicology and drug analysis for safe integration.
Abstract
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psiloc...
Psychedelic use and psychological flexibility: The role of meaningful intention and decentering
Journal of Psychedelic Studies – August 16, 2024
Summary
Meaningful intention and decentering during psychedelic experiences significantly enhance psychological flexibility, a crucial aspect of mental well-being. Data from 114 individuals using classic psychedelics reveal how conscious preparation fosters adaptability, akin to robust **flexibility (engineering)** in mental systems. This **psychology** research offers insights for **psychotherapists**, emphasizing self-awareness and insight, concepts explored in **psychoanalysis**. **Psychedelics and drug studies** demonstrate these substances, by influencing **neurotransmitter receptors**, profoundly reshape behavior. Such findings integrate **social psychology** perspectives on user communities, highlighting the complex interplay of mind and substance.
Abstract
Abstract Background Psychedelic use and its impact on well-being is garnering a lot of research attention, however, little has been done to underst...
Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness
Drug Science Policy and Law – April 01, 2025
Summary
Psychedelics show promise for mental health, but a large-scale analysis of 596,187 individuals reveals a critical disparity. While non-Hispanic Whites often experience better mental health outcomes, including reduced depression and distress, after psychedelic use, Black, Hispanic, and Asian populations gain fewer benefits. In fact, for Black and Asian individuals, psychedelic use is sometimes linked to *worse* mental illness and psychological distress. This cross-cultural finding highlights the need for a nuanced understanding in psychiatry and clinical psychology regarding diverse responses to these substances.
Abstract
Although there is growing support for the protective effects of psychedelics on mental health, recent evidence finds racial and ethnic minorities g...
Herbal Resources in the medication of depression during pandemic COVID-19
Acta Poloniae Pharmaceutica - Drug Research – May 10, 2022
Summary
The 2019-20 coronavirus outbreak significantly worsened mental health, with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exacerbating clinical depression. Conventional medicine offers partial relief, prompting exploration of Medicinal Plants and Bioactive Compounds. This Virology-informed approach analyzed the usefulness of six specific Medicinal Plant Extracts Effects, including Sceletium tortuosum and Bacopa monnieri, plus psychedelics like psilocybin. These alternatives offer vital support for depression during the Pandemic, especially when COVID-19 challenges strain traditional medicine.
Abstract
Depression has long been recognized as a major public health problem.Fear and anxiety associated with the high morbidity and mortality of COVID-19 ...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
OpenAlex – July 18, 2023
Summary
A systematic review of 33 psychedelic clinical trials revealed significant underreporting of crucial psychosocial interventions, impacting treatment outcomes in Psychiatry and Clinical psychology. For example, 82% of trials did not assess treatment fidelity. Drawing from MEDLINE and PsycINFO, the systematic review used a Checklist based on Consolidated Standards of Reporting Trials to examine reporting of psychological intervention by psychotherapists, including those administering psilocybin. Such reporting gaps hinder standardization in Medicine and Psychedelics and Drug Studies, crucial for Mental Health Research Topics.
Abstract
Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the rol...
Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review
Advances in Mental Health – July 13, 2023
Summary
People with eating disorders experienced significant symptom reduction and even complete remission following psychedelic use, including psilocybin. This review of six studies suggests a promising role for hallucinogens in clinical psychology and psychiatry. Participants reported profound spiritual healing, gaining insights into the psychological origins of their eating disorders, and reduced anxiety. While preliminary, these findings highlight the potential of psychedelics in medicine. Rigorous clinical trials are now essential to confirm efficacy for eating disorders, informing future drug studies and advancing our understanding of these compounds' influence on behavior.
Abstract
Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) an...
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Current Psychiatry Research and Reviews – January 21, 2024
Summary
Psychedelics, including psilocybin and MDMA, are re-emerging in Psychiatry as potent Medicine for mental illness. Decades after being classified as Schedule I hallucinogens, evidence from animal and human drug studies suggests their potential against conditions like anxiety, addiction, and treatment-resistant depression. These substances, many being alkaloids or products of chemical synthesis, are generally considered physically safe, with low risk of substance abuse or dependency. Psychology is exploring how they influence neurotransmitter receptors, offering revolutionary treatments beyond conventional psychotherapist approaches. Careful management is crucial to ensure their medical role.
Abstract
: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems...
Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study
Journal of Psychoactive Drugs – May 30, 2025
Summary
Public sentiment towards psychedelics like psilocybin and LSD is surprisingly neutral to slightly positive, contrasting sharply with highly negative views on substances like heroin. Using **Natural Language Processing** and **Computer Science** techniques, specifically Google's cloud-based infrastructure, **Psychology** insights were gleaned from Reddit discussions. This approach effectively captured public perception in **Psychedelics and Drug Studies**, suggesting growing acceptance of therapeutic potential. **Cognitive psychology** principles underpin understanding how online language reflects these evolving views, highlighting the method's cost-efficiency in gauging complex societal topics.
Abstract
New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychede...
Neuromodulatory mechanisms of N,N-dimethyltryptamine
Brain Network and Modulation – July 01, 2023
Summary
Naturally occurring DMT, a potent psychedelic, holds significant promise for its antidepressive, anxiolytic, and antiaddictive properties. Neuroscience and Neuropharmacology Research reveals its complex chemistry profoundly influences behavior. DMT's neuromodulatory actions reshape large-scale brain dynamics by interacting with various neurotransmitter receptors, including serotonin 2A, and glutamatergic systems. This alters perception and enhances bottom-up processing. Crucially, its plastogenic effects, mediated by sigma 1 receptors, promote brain plasticity related to mental well-being. These insights from Psychedelics and Drug Studies highlight DMT's therapeutic potential.
Abstract
N,N-dimethyltryptamine (DMT) is the simplest psychedelic tryptamine and is produced naturally by many plant and animal species, including humans. W...
Psychedelics for depression: from neurobiology to treatment
European Psychiatry – March 01, 2023
Summary
Remarkably, a single or double dose of psilocybin, a potent hallucinogen, can achieve remission in patients with treatment-resistant depression. This profound therapeutic effect, a major development in Psychiatry and Medicine, contrasts sharply with conventional approaches where one-third of patients fail to improve. The rapid onset of this therapeutic approach is fueling interest in Psychology and Psychedelics and Drug Studies. Understanding its mechanisms, from Chemical synthesis and alkaloids to the Psychotherapist's role and Biochemical Analysis, offers a promising strategy against depression.
Abstract
Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic poten...
Chapter 51. Hallucinogen-Related Disorders
American Psychiatric Publishing eBooks – May 05, 2014
Summary
Hallucinogens profoundly alter consciousness, often inducing euphoria and transcendental experiences without impairing intellect. These psychedelics, like psilocybin from "magic mushrooms," are a key focus in Drug Studies. Plant-based Medicinal Research investigates their natural origins, while Biochemical Analysis and Sensing Techniques illuminate their impact on psychology and psychiatry. Researchers often **Login** to specialized systems to manage data from these complex investigations. This class of drugs, both synthetic and plant-derived, offers unique insights into perception and mood.
Abstract
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well...
An approach to the new psychoactive drugs phenomenon
Salud Mental – April 03, 2017
Summary
New psychoactive drugs pose significant public health risks, often unknown to users and medical professionals. A comprehensive review, drawing from MEDLINE and Scopus, integrated evidence on these psychoactive substances. It covered the epidemiology, psychopharmacology, and medical complications of various drugs, including synthetic cannabinoids and synthetic cathinones like Mephedrone. This analysis of drug consumption trends is crucial for medicine, psychiatry, and psychology, informing fields like Forensic Toxicology and Drug Analysis, and Psychedelics and Drug Studies, especially regarding neurotransmitter receptor influence on behavior.
Abstract
Background. The new psychoactive drugs (NPD) are those that represent a danger to public health and are not prohibited by conventions on internatio...
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports – May 16, 2024
Summary
A "psychedelic renaissance" reveals hallucinogens like psilocybin offer rapid, sustained therapeutic effects for mental health. Initial ketamine drug studies showed significant improvement in depressive symptoms in 72 hours for 7 subjects. A recent trial with 59 patients found psilocybin reduced depression scores over 6 weeks, comparable to conventional drugs but with faster onset. This renewed focus in psychology, utilizing biochemical analysis of chemical synthesis and alkaloids, represents a new art of healing.
Abstract
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various di...
THE BENEFITS OF PSYCHEDELIC THERAPY FOR MENTAL HEALTH: EXPLORING PSYCHEDELICS
Zenodo (CERN European Organization for Nuclear Research) – May 13, 2022
Summary
Psychedelic psychotherapy shows profound promise for mental health. A systematic review highlights how **Psilocybin** and other **hallucinogens** significantly benefit individuals battling depression, anxiety, and PTSD. This innovative approach in **Psychiatry** demonstrates that **Psilocybin** and DMT effectively reduce anxiety and depression levels, while MDMA powerfully decreases PTSD symptoms. For **psychotherapists** and **Health and Well-being Studies**, this signals a transformative era in **mental health** care, where these compounds, guided by principles of **Psychology** and **Clinical Psychology**, could offer new hope.
Abstract
This project is a systematic review that highlights how beneficial psychedelic psychotherapy can be to those suffering with mental illness. The thr...
An ontology of psychedelic entity experiences in evolutionary psychology and neurophenomenology
Journal of Psychedelic Studies – March 26, 2018
Summary
Encounters with psychedelic entities, from spirit guides to angels, fundamentally mirror diverse human conceptions, revealing a profound basis in our **evolutionary psychology**. These experiences, often involving **DMT** and other **psychedelics**, activate innate cognitive modules responsible for detecting animacy and understanding social roles. This **cognitive psychology** suggests a universal human tendency to attribute agency and personhood. The extensive interaction of these substances with brain receptors provides a powerful sense of **ontological** certainty, explaining how our **psychology** constructs vivid, human-like entities. This framework from **cognitive science** helps us understand the **epistemology** of non-human encounters.
Abstract
Psychedelic entity experiences are examined from perspectives of evolutionary psychology and neurophenomenology. Their similarities with other enti...
0391 Racial/Ethnic Differences in Psychedelic Use and Sleep Satisfaction: Preliminary Findings from the Herbal Heart Study
SLEEP – May 01, 2025
Summary
A surprising finding in psychology highlights a complex link between psychedelic use and sleep satisfaction. Among 200 young adults, particularly within the Hispanic/Latino ethnic group, consuming psychedelics was associated with significantly poorer sleep. For instance, 33.9% of Hispanic/Latino psychedelic users reported sleep dissatisfaction, compared to 17.2% of non-users. Psilocybin users in this group faced 9.2 times higher odds of dissatisfaction. This insight from drug studies informs future medicine, clinical psychology, and psychiatry, emphasizing tailored support for sleep health.
Abstract
Abstract Introduction Research on psychedelic use and sleep satisfaction remains unclear despite increased use. This study examines the psychedelic...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Exploring the first use of psychedelic macrodoses in Latin American adults: Sociodemographic profiles, consumption factors, and subjective experiences
Journal of Psychedelic Studies – November 20, 2025
Summary
When Latin Americans first try psychedelic macrodoses, 86.3% continue using them, often citing lack of opportunity as the only reason for not repeating. A survey of 4,810 adults found psilocybin mushrooms (57.6%) and LSD (33.3%) were most common, primarily for recreational (70.5%) or spiritual (21.6%) purposes. Most consumed with friends (65.7%). Psilocybin was linked to introspection, MDMA to empathy. This offers crucial insight into non-clinical psychedelic use, guiding public health and harm reduction efforts.
Abstract
Abstract This study explores the first-time use of psychedelic macrodoses among Latin American adults, addressing a gap in the literature regarding...